RSV Immunisation Status in Queensland (Australia)

Study of Immunisation Rates for RSV in Queensland Infants

Recruiting
18 years or above
All
Phase N/A
1200 participants needed
1 Location

Study Overview

The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.

The study will focus on:

1. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland.

Secondary objectives of this study are as follows:

  1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab.

    1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation.
    2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact.
  2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland.
  3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: RSV Immunization
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Be a parent of an infant born between 1 February 2024 and 15 April 2025
  • Be at least 18 years of age
  • Reside in Queensland, Australia
  • Read and agree to the Participant Information and Consent Form (PICF) before proceeding to the survey
  • Agree with Adverse Event (AE) reporting requirements before proceeding to the survey

Exclusion Criteria:

- Have participated in any studies on infant respiratory diseases in the past 4 months

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

This study investigates the immunisation rates for Respiratory Syncytial Virus (RSV) in infants in Queensland, Australia. The purpose is to understand how many eligible infants receive the investigational medication during their first RSV season.

The study evaluates factors influencing parental decisions regarding immunisation and examines demographic impacts. It also looks at immunisation rates in various subgroups and compares these with data from the Australian Immunisation Register.

  • Who can participate: Parents of infants born between 1 February 2024 and 15 April 2025, who are at least 18 years old and reside in Queensland, Australia.
  • Study details: Participants will provide information through a survey. The study will collect data on immunisation decisions and demographic factors.
Updated on 22 Jun 2026. Study ID: NCT07615192

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language